NCT03290794View on ClinicalTrials.gov

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

November 25, 2022

Study Completion Date

May 26, 2023

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

Aflibercept (Eylea, BAY86-5321)

Intravitreal Aflibercept as prescribed by the treating Physician

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03290794 - Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice | Biotech Hunter | Biotech Hunter